Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Inclusion Criteria: * newly diagnosed or diagnosis of relapsing (relapsed \<= 6 weeks to baseline) mild to moderate ulcerative colitis * women not of childbearing potential or WOCP who agreed to use an effective contraceptive method Exclusion Criteria: * severe ulcerative colitis or relapsed for \> 6 weeks prior to baseline * subjects who had relapsed on maintenance therapy with doses of mesalazine \> 2.0 g/day * subjects with Crohn's disease, proctitis, bleeding disorders or active peptic ulcer disease * subjects with asthma if they were known to be mesalazine-sensitive * subjects who were at immediate or significant risk of toxic megacolon * subjects who had previous resective colonic surgery * subjects who had moderate or severe renal impairment